Thoracic SMARCA4-deficient undifferentiated tumor-pathological diagnosis and combined immune checkpoint inhibitor treatment.
- Author:
Yan XIONG
1
;
Bo ZHANG
2
;
Li Gong NIE
3
;
Shi Kai WU
4
;
Hu ZHAO
5
;
Dong LI
1
;
Ji Ting DI
1
Author Information
1. Department of Pathology, Peking University First Hospital, Beijing 100034, China.
2. Department of Pathology, School of Basic Medical Sciences Peking University/Peking University Third Hospital, Beijing 100191, China.
3. Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China.
4. Department of Oncology, Peking University First Hospital, Beijing 100034, China.
5. Department of Thoracic Surgery, Peking University First Hospital, Beijing 100034, China.
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitor;
Neoadjuvant therapy;
Pathological assessment;
Programmed cell death 1-ligand 1;
Thoracic SMARCA4-deficient undifferentiated tumor;
Tumor mutation burden
- MeSH:
Humans;
Immune Checkpoint Inhibitors;
Neoplasm Recurrence, Local;
Lung Neoplasms/genetics*;
Thoracic Neoplasms/pathology*;
Adenocarcinoma;
DNA Helicases;
Nuclear Proteins;
Transcription Factors
- From:
Journal of Peking University(Health Sciences)
2023;55(2):351-356
- CountryChina
- Language:Chinese
-
Abstract:
We explored clinicopathological features and treatment strategies for thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT). Thoracic SMARCA4-UT is a new entity recently acknowledged in the 2021 edition of World Health Organization Classification of Thoracic Tumors, and doctors are relatively unfamiliar with its diagnosis, treatment, and prognosis. Taking a case of SMARCA4-UT treated in Peking University First Hospital as an example, this multi-disciplinary discussion covered several hot issues on diagnosing and treating thoracic SMARCA4-UT, including histological features, immu- nohistochemical and molecular phenotype, immune checkpoint inhibitor (ICI) therapy, and pathological assessment of neoadjuvant therapy response. The patient was an older man with a long history of smoking and was admitted due to a rapidly progressing solid tumor in the lower lobe of the right lung. Histologically, tumor cells were epithelioid, undifferentiated, diffusely positive for CD34, and partially positive for SALL4.The expression of BRG1 protein encoded by SMARCA4 gene was lost in all of tumor cells, and next-generation sequencing(NGS)confirmed SMARCA4 gene mutation (c.2196T>G, p.Y732Ter). The pathological diagnosis reached as thoracic SMARCA4-UT, and the preoperative TNM stage was T1N2M0 (ⅢA). Tumor proportion score (TPS) detected by immunohistochemistry of programmed cell death 1-ligand 1 (PD-L1, clone SP263) was 2%. Tumor mutation burden (TMB) detected by NGS of 1 021 genes was 16. 3/Mb. Microsatellite detection showed the tumor was microsatellite stable (MSS). Neo-adjuvant therapy was implemented with the combined regimen of chemotherapy and ICI. Right lower lobectomy was performed through thoracoscopy after the two weeks' neoadjuvant. The pathologic assessment of lung tumor specimens after neoadjuvant therapy revealed a complete pathological response (CPR). The post-neoadjuvant tumor TNM stage was ypT0N0M0. Then, five cycles of adjuvant therapy were completed. Until October 2022, neither tumor recurrence nor metastasis was detected, and minimal residual disease (MRD) detection was negative. At present, it is believed that if BRG1 immunohistochemical staining is negative, regardless of whether SMARCA4 gene mutation is detected, it should be classified as SMARCA4-deficient tumors. SMARCA4-deficient tumors include a variety of carcinomas and sarcomas. The essential criteria for diagnosing SMARCA4-UT includes loss of BRG1 expression, speci-fic histological morphology, and exclude other common thoracic malignant tumors with SMARCA4-deficiency, such as squamous cell carcinoma, adenocarcinoma and large cell carcinoma. SMARCA4-UT is a very aggressive malignant tumor with a poor prognosis. It has almost no targeted therapy mutations, and little response to chemotherapy, but ICI is currently the only effective drug. The successful diagnosis and treatment for this case of SMARCA4-UT should enlighten significance for various kinds of SMARCA4-deficient tumors.
